| 产品描述: | PF-05221304 是一种具有口服活性的肝脏靶向乙酰辅酶A羧化酶 (ACC) 抑制剂,ACC 是脂肪酸合成的限速酶。 |
| 靶点: |
Acetyl-CoACarboxylase |
| 体外研究: |
PF-05221304 blocked polarization of human T cells to proinflammatory but not anti-inflammatory T cells, and suppressed activation of primary human stellate cells to myofibroblasts in vitro, showing direct effects on inflammation and fibrogenesis. |
| 体内研究: |
PF-05221304 reduced markers of inflammation and fibrosis in the diethylnitrosamine chemical-induced liver injury model and the choline-deficient, high-fat-fed rat model. |
| 参考文献: |
1.Ross T T , Crowley C , Kelly K L , et al. Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems[J]. Cellular and Molecular Gastroenterology and Hepatology, 2020, 10(4). |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.99 ml |
9.949 ml |
19.898 ml |
| 5 mM |
0.398 ml |
1.99 ml |
3.98 ml |
| 10 mM |
0.199 ml |
0.995 ml |
1.99 ml |
| 50 mM |
0.04 ml |
0.199 ml |
0.398 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |